期刊文献+

以甲基转移酶抑制剂为基础联合治疗中高危MDS/AML研究现状

Progress in combined treatments of myelodysplastic syndrome and acute myeloid leukemia based on DNA methyltransferaseinhibitors.
收藏 分享 导出
摘要 甲基转移酶(DNMT)抑制剂通过表观遗传学调控发挥治疗作用。由于DNMT抑制剂单药治疗骨髓增生异常综合征(MDS)疗效的局限性,以DNMT抑制剂为基础的联合治疗不断被研究和试用于临床。临床试验表明,DNMTs与靶向药物如组蛋白乙酰化酶抑制剂、免疫调节剂来那度胺等的联合在治疗MDS和部分急性髓系白血病(AML)疗效优于单药治疗。而近年来与传统化疗药物的联合在中高危MDS及AML的疗效也初露端倪。但对于高危MDS及难治AML,以DNMT抑制剂为基础的联合治疗方案仍有许多问题需要进一步探索和研究。 DNA methyltransferase(DNMT) inhibitors,a prototype of epigenetic regulation, exert the therapeutic action on acute myeloid leukemia(AML) and myelodysplastic syndrome(MDS). Due to the limited efficacy of monotherapy ofDNMT inhibitors in AML and MDS,numerous clinical trials of DNMT inhibitor-based combination modality therapies are under research. Some clinical trials indicate that DNMT inhibitors combined with either targeted drugs like histone acetylation enzyme inhibitors or immune regulator drugs like lenalidomide are superior to the monotherapy of DNMT inhibitors.In recent years,DNMT inhibitors combined with traditional chemotherapy for high-risk MDS and AML have shown some effects.However, DNMT inhibitor-based combination modality therapies for high-risk MDS and refractory AML still need researching.
作者 李空飞 佟红艳 LI Kong-fei,TONG Hong-yan.(Department of Hematology, the First Affiliated Hospital of Zhejiang University College of Medicine,Hangzhou 310003,China)
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2015年第2期118-122,共5页 Chinese Journal of Practical Internal Medicine
基金 国家自然科学基金(30870914,81270582,81470290) 浙汀省自然科学基金杰出青年项目(LR12H08001) 浙江省科技厅晕大项目(20l3e03043-2) 浙江省卫生厅支撑学科项目(201234445,2012ZDA013):浙江省中医药局(2012ZA071) 卫生部公益性行业科研专项经费项目(201202017)
关键词 甲基化转移酶抑制剂 骨髓增生异常综合征 急性髓系白血病 地西他滨 DNA methyltransferase inhibitors myelodysplastic syndrome acute myeloid leukemia Decitabine
作者简介 通信作者:佟红艳,电子信箱:hongyantong@aliyun.com
  • 相关文献

参考文献31

  • 1Claus R, FliegaufM, Stock M, et al. Inhibitors of DNA methylation andhistone deacetylation independently relieve AML 1 /ETO-mediatedlysozyme repression[j]. J Leukoc Biol, 2006, 80: 1462-1472. 被引量:1
  • 2Folio MY, Finelli C, Mongiorgi S, et al. Synergistic induction of PI-PLCbetal signaling by azacitidine and valproic acid in high-riskmyelodysplastic syndromes [J]. Leukemia, 2011, 25: 271-280. 被引量:1
  • 3Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, et al. Final resultsof a phase I/II study of the combination of the hypomethylating agent5-aza-2,-deoxycytidine(DAC)and the histone deacetylase inhibitorvalproic acid(VPA)in patients with leukemia[j]. Blood, 2005,106: 408. 被引量:1
  • 4Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferaseand histone deacetylase inhibition in the treatment of myeloidneoplasms [J]. Cancer Res, 2006,66: 6361-6369. 被引量:1
  • 5Kirschbaum M, Gojo I, Goldberg SL, et al. A phase I clinical trialof vorinostat in combination with decitabine in patients with acutemyeloid leukaemia or myelodysplastic syndrome [J]. BrJ Haematol,2014,167(2):185-193. 被引量:1
  • 6Burke MJ, Lamba JK, Pounds S, et al. A therapeutic trial of decitabineand vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia[J]. Am J Hematol, 2014, 89. 被引量:1
  • 7List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide inmyelodysplastic syndromes[j]. N EnglJ Med, 2005, 352: 549-557. 被引量:1
  • 8Arati R, Ghazi K, David A, et al. Phase I Study of Lenalidomide andDecitabine for high and intermediate 2 risk MDS [J]. Blood, 2012, 120:Abstract 4935. 被引量:1
  • 9Peng CY, Jiang J, Zheng HT, et al. Growth-inhibiting effects of arsenictrioxide plus epigenetic therapeutic agents on leukemia cell lines[J]_Leuk Lymphoma, 2010, 51: 297-303. 被引量:1
  • 10Welch JS, KIcoJM, Gao F, et al. Combination decitabine, arsenic trioxide,and ascorbic acid for the treatment of myelodysplastic syndrome andacute myeloid leukemia: a phase I study [J]. AmJ Hematol, 2011,86:796-800. 被引量:1

二级参考文献37

共引文献51

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈
新型冠状病毒肺炎防控与诊疗专栏